CTOs on the Move

JOINN Biologics

www.joinnbio.com

 
JOINN Biologics is a Bay Area, California-based CMO company that is committed to the advancement of biopharmaceutics through its premier contract development and manufacturing services for biologics and advanced therapies. JOINN Biologics aims to provide a complete range of services from early custom development to clinical manufacturing for our global clients. We will work closely with our partners and clients to further accelerate the development of high-quality biologics to meet patient`s needs and deliver long-lasting value to biopharmaceutical industry.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.joinnbio.com
  • 2600 Hilltop Drive
    Richmond, CA USA 94806
  • Phone: 510.295.0222

Executives

Name Title Contact Details

Funding

JOINN Biologics raised $60M on 12/10/2019

Similar Companies

Nova Health

Nova Healths medical professionals provide treatment for urgent care, primary care and physical therapy services throughout the Western US.

Kamada

Kamada is focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins. AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. The Company`s flagship product is GLASSIA®, the first liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets GLASSIA® in the U.S. through a strategic partnership with Baxalta (now part of Shire plc) and in other counties through local distributors. In addition to GLASSIA®, Kamada has a product line of six other pharmaceutical products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America and Asia. Kamada`s rabies immune globulin (Human) product received FDA approval for Post-Exposure Prophylaxis against rabies infection and is marketed in the U.S. through a partnership with Kedrion Biopharma. Kamada has late-stage products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency and, in addition, its intravenous AAT is in development for other indications, such as type-1 diabetes, GvHD and prevention of lung transplant rejection. Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing more than 10 complementary products in Israel that are manufactured by third parties.

Focus Express Mail Pharmacy Inc

Focus Express Mail Pharmacy Inc is a Horsham, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Landos Biopharma

Landos pursues safer, more effective first-in-class oral therapeutics for autoimmune disorders at an accelerated rate.